BaseLaunch is excited to announce the extension of the partnership with CSL, a global biotech leader. Together, we're committed to driving innovation in healthcare. CSL’s…
We are pleased to announce a partnership with VISCHER, a respected Swiss law firm known for its commitment to providing startups, entrepreneurs and investors with…
We are delighted to announce that KPMG, is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and grow their…
FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s…
BASEL, Switzerland, 18 January 2024 - Synendos Therapeutics AG, a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that it has received approval…
Basel, Switzerland – Alentis Therapeutics , a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Dr. William…
Novo Nordisk has become the latest partner to join BaseLaunch. Novo Nordisk joins other world-class pharma, venture fund and biotechnology partners - Roche, Johnson &…
Basel, Switzerland, 13 December, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased…
Ferring Pharmaceuticals and PharmaBiome announced a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring…
TOLREMO today announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its…